BARDA has 24 million bucks in chump change to fund Phase 2 clinical trial of CRISPR technology for treating urinary tract infections caused by anti-biotic resistant E-coli

You might think that this same amount was available to fund Phase 2 and 3 studies on IVM and HCQ, but that would make you a whiner, right?

From here:

BARDA commits $24 million to support phase 2 trial for bacteriophage therapy | CIDRAP (umn.edu)

“Locus Biosciences announced yesterday that it's received $23.9 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to continue developing its CRISPR-enhanced bacteriophage therapy for treating urinary tract infections (UTIs) caused by antibiotic-resistant Escherichia coli.”

If you think 24 million bucks is a lot of money, there’s more!

“The funding is part of an $85 million contract between BARDA and the North Carolina-based biotechnology company and will be used to advance LBP-EC01—a bacteriophage cocktail engineered with a CRISPR-Cas3 construct that targets the E coli genome—into the second part of the ELIMINATE phase 2 trial. In the first part of the trial, LBP-EC01 in combination with trimethoprim/sulfamethoxazole demonstrated safety and tolerability in patients with uncomplicated UTIs.”

The 24 million is just part of an 85-million-dollar contract.

One can only assume that if it works here, it can be also used to remove the E-coli contaminants in the C19 modified mRNA spike venom injections?

Seems like there are a lot of women with E coli urinary tract infections around the world.

“Uncomplicated UTIs, 80% of which are caused by E coli, are one of the most common reasons for outpatient antibiotic prescribing in the United States and other parts of the world, affecting more than 150 million people each year.”

With 4 billion women on the planet that would mean almost 4% have this sort of UTI and no other forms of UTI? (I wonder how many women or wives in BARDA suffer from this).

“Part two of the placebo-controlled trial will evaluate the efficacy of the combination in adult women with uncomplicated UTIs caused by drug-resistant E coli.”

I wonder how the placebo group in the trial can access women with UTI’s who are not being treated with other protocols – maybe there will be several placebos – for untreated UTI’s and UTI’s being treated with alternatives.

Diagnosis and Management of Uncomplicated Urinary Tract Infections | AAFP

An uncomplicated UTI is defined here:

Uncomplicated Urinary Tract Infections - StatPearls - NCBI Bookshelf (nih.gov)

“An uncomplicated urinary tract infection (UTI) is a bacterial infection of the bladder and associated structures. Patients with uncomplicated UTIs have no structural abnormality of the urinary tract and no comorbidities such as diabetes, an immunocompromised state, recent urologic surgery, or pregnancy. An uncomplicated UTI is also known as cystitis or a lower tract UTI.”

Ah, cystitis.

Will the trial feature only unvaxxed women or those whose last injection of spike venom was over two years ago? How will they reflect the effects of the spike venom and its E-coli and other contaminants?

Interesting times.

Still, if CRISPR proves effective against drug resistant E-coli, maybe it will also prove effective against drug resistant tuberculosis!!!

Hey, maybe CRISPR can be programmed into nanobots that can receive instructions to kill off any bad proteins, viruses or contaminants like metals via 5G!

Makes you wonder just what BARDA is working on and how big its budget is for clinical trials and other research, right?

From page 7 of 34 here:

2021_Wellcome-FEAM-HERA-report.pdf

The EU is copying BARDA and quotes this for BARDA’s budget (which the EU will magnify by 5 times to suit its purposes).

“BARDA’s mandate is to anticipate and prepare for chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza and emerging infectious diseases. BARDA’s budget reflects its ambition: for 2021 it was granted a budget of USD 1.4 billion.”

BARDA funding of 1.4 billion in 2021 – a year after the pandemic started. Surely that can’t be right? That would mean the 85 million for the UTI clinical trial 6% of an entire year’s budget!

Interestingly, Wikipedia has this as part of it entry for BARDA:

“In FY 2020, the annual budget of BARDA was approximately $1.6 billion depending on the precise allocation of costs, including the costs of projects overseen or managed by BARDA on behalf of the ASPR.[10][11][12]

The proposed budget in FY 2020, not reflecting any additional congressional appropriations due to the COVID-19 crisis, was an increase from $1.27 billion in FY 2019, and $1.02 billion in FY 2018.

This figure included $512 million in medical countermeasures including $192 million for combating antibiotic-resistant bacteria[13] and $260 million USD for advanced research and development (ARD).”

I am sure it all makes sense to someone and is subject to the most rigorous Congressional scrutiny and accountability!

Onwards!

Please subscribe or donate via Ko-fi – any amount from 3 bucks upwards. Don’t worry and God Bless, if you can’t or don’t want to. Ko-fi donations here: https://ko-fi.com/peterhalligan - an annual subscription of 100 bucks is one third less than a $3 Ko-fi donation a week!